Eli Lilly and Co (LLY) : Argentiere Capital Ag has sold out all of its stake in Eli Lilly and Co during the most recent quarter, according to the disclosure filed by the company on Aug 9, 2016 with the SEC. The investment management company has sold out 18,390 shares of Eli Lilly and Co which is valued at $1,481,498.
Other Hedge Funds, Including , Winslow Asset Management Inc boosted its stake in LLY in the latest quarter, The investment management firm added 830 additional shares and now holds a total of 69,706 shares of Eli Lilly and Co which is valued at $5,688,010. Eli Lilly and Co makes up approx 1.21% of Winslow Asset Management Inc’s portfolio. Harel Insurance Investments Financial Services Ltd. added LLY to its portfolio by purchasing 1,805 company shares during the most recent quarter which is valued at $149,310. Eli Lilly and Co makes up approx 0.02% of Harel Insurance Investments Financial Services Ltd.’s portfolio.Winslow Evans Crocker boosted its stake in LLY in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 7,842 shares of Eli Lilly and Co which is valued at $639,829. Eli Lilly and Co makes up approx 0.18% of Winslow Evans Crocker’s portfolio.Country Club Trust Company N.a. reduced its stake in LLY by selling 1,700 shares or 36.23% in the most recent quarter. The Hedge Fund company now holds 2,992 shares of LLY which is valued at $244,117. Eli Lilly and Co makes up approx 0.03% of Country Club Trust Company N.a.’s portfolio.
Eli Lilly and Co opened for trading at $80.16 and hit $80.35 on the upside on Wednesday, eventually ending the session at $80.11, with a gain of 0.34% or 0.27 points. The heightened volatility saw the trading volume jump to 25,19,548 shares. Company has a market cap of $88,429 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.